Magnolia Capital Advisors LLC acquired a new stake in shares of Medtronic PLC (NYSE:MDT) during the 4th quarter, Holdings Channel.com reports. The fund acquired 2,918 shares of the medical technology company’s stock, valued at approximately $331,000.
Several other institutional investors have also added to or reduced their stakes in MDT. UMA Financial Services Inc. purchased a new stake in shares of Medtronic in the 3rd quarter worth $370,000. Voya Investment Management LLC boosted its stake in shares of Medtronic by 12.2% in the third quarter. Voya Investment Management LLC now owns 1,533,709 shares of the medical technology company’s stock worth $166,591,000 after buying an additional 166,811 shares during the last quarter. Merit Financial Group LLC boosted its position in Medtronic by 2.5% during the third quarter. Merit Financial Group LLC now owns 4,445 shares of the medical technology company’s stock worth $483,000 after purchasing an additional 108 shares in the last quarter. MV Capital Management Inc. boosted its position in Medtronic by 6.9% during the third quarter. MV Capital Management Inc. now owns 3,550 shares of the medical technology company’s stock worth $386,000 after purchasing an additional 229 shares in the last quarter. Finally, High Falls Advisors Inc purchased a new position in Medtronic during the third quarter worth approximately $207,000. 82.55% of the stock is currently owned by institutional investors.
A number of brokerages have issued reports on MDT. UBS Group increased their price target on Medtronic from $127.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 16th. Needham & Company LLC downgraded Medtronic from a “strong-buy” rating to a “buy” rating and lowered their price target for the stock from $134.00 to $109.00 in a research report on Monday. BTIG Research lowered their price target on Medtronic from $124.00 to $102.00 and set a “buy” rating on the stock in a research report on Monday. ValuEngine downgraded Medtronic from a “hold” rating to a “sell” rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their price target on Medtronic from $122.00 to $128.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $117.85.
Shares of MDT traded down $1.20 during midday trading on Tuesday, hitting $90.85. 6,695,824 shares of the stock were exchanged, compared to its average volume of 10,279,906. Medtronic PLC has a 52-week low of $72.13 and a 52-week high of $122.15. The stock has a fifty day simple moving average of $99.62 and a 200 day simple moving average of $108.80. The firm has a market cap of $120.47 billion, a P/E ratio of 23.06, a P/E/G ratio of 2.25 and a beta of 0.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.28 and a current ratio of 2.75.
Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 18th. The medical technology company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.38 by $0.06. The business had revenue of $7.72 billion during the quarter, compared to analyst estimates of $7.80 billion. Medtronic had a return on equity of 14.76% and a net margin of 17.11%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the business posted $1.29 earnings per share. As a group, equities research analysts forecast that Medtronic PLC will post 5.64 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.54 dividend. The ex-dividend date of this dividend is Thursday, March 26th. This represents a $2.16 dividend on an annualized basis and a yield of 2.38%. Medtronic’s dividend payout ratio (DPR) is presently 41.38%.
Medtronic Company Profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.